Integral Diagnostics delivered a strong FY26 result with revenue climbing 25.6% to $788.7 million, demonstrating the material contribution from its Capitol Health merger completed in December 2024. Operating EBITDA reached $164.8 million with margin expansion to 20.9%, up 80 basis points year-on-year and tracking to management’s guidance. The result reflects both organic growth momentum and significant synergy capture from the merger.
The merger integration has delivered $14 million in annual synergies, exceeding the $10 million guided at announcement. This outperformance stems from group procurement efficiencies and increased teleradiology scale. Operating costs have benefited from leverage as revenue has grown, with the company achieving operating NPAT growth of 50.1% to $47.4 million. The operating metrics exclude $25.4 million in non-recurring integration costs, highlighting management’s clean separation of ongoing operational performance from one-time transaction impacts.
Capital management has been a clear focus. Net leverage improved to 2.3 times EBITDA from 2.6 times despite the significant acquisition, reflecting strong cash generation and disciplined balance sheet management. The company has hedged 51.2% of gross debt at favourable rates relative to current BBSY levels, providing downside protection in a rising rate environment. Operating free cash flow of $106.4 million underpins the balance sheet strength and capital returns.
Shareholder returns have accelerated materially. Operating diluted EPS grew 23.6% to 12.6 cents per share, while the final dividend per share surged 50% to reflect both earnings growth and confidence in sustainable cash generation. This progressive dividend approach signals management’s conviction in underlying earnings power and cash conversion.
The company is well positioned for the next phase of growth. Three government initiatives offer structural tailwinds: MRI deregulation will expand the addressable market, the National Lung Cancer Screening Program represents a new revenue stream, and the GP Bulk Billing Incentive Program should drive utilisation across facilities. The patient Net Promoter Score of 81 and strong referrer satisfaction indicate healthy underlying demand dynamics. The organisational structure refinement mentioned in the presentation suggests management is optimising the combined entity for growth.
Investors should monitor synergy realisation progress against the elevated $14 million run-rate target, organic growth momentum independent of the merger, and leverage trajectory as the company moves through the deleveraging cycle. The hedging position is also worth tracking as interest rate conditions evolve. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Integral Diagnostics Limited (ASX: IDX)
Integral Diagnostics Limited is a healthcare services company providing diagnostic imaging services including magnetic resonance imaging, positron emission tomography, computed tomography, mammography, interventional radiology, ultrasound, and radiography. The company serves general practitioners, medical specialists, and allied health professionals across Australia and New Zealand. Founded in 1967, it operates from Melbourne, Australia.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
